

# SIX-YEAR FINANCIAL SUMMARY

Mitsubishi Tanabe Pharma Corporation and Consolidated Subsidiaries  
Years ended March 31

	2009	2008 <sup>1</sup>	2007	2006	2005	2004
<b>Financial figures (millions of yen):</b>						
Net sales						
Tanabe Seiyaku	<b>¥414,752</b>	¥315,636	¥177,531	¥171,552	¥171,984	¥173,613
Mitsubishi Pharma		[409,427]	227,517	236,207	234,244	235,431
Cost of sales						
Tanabe Seiyaku	<b>158,184</b>	113,471	69,051	61,935	63,609	63,714
Mitsubishi Pharma		[150,535]	79,996	81,444	81,712	83,812
Selling, general and administrative expenses						
Tanabe Seiyaku	<b>184,874</b>	148,225	78,120	82,057	80,870	80,484
Mitsubishi Pharma		[186,423]	107,566	118,528	121,483	122,892
Operating income						
Tanabe Seiyaku	<b>71,694</b>	54,024	30,456	27,568	27,467	29,440
Mitsubishi Pharma		[72,468]	39,955	36,235	31,049	28,727
Net income						
Tanabe Seiyaku	<b>26,532</b>	21,993	20,174	15,466	15,902	17,687
Mitsubishi Pharma		[31,932]	24,305	20,699	13,172	10,818
R&D expenses						
Tanabe Seiyaku	<b>73,122</b>	59,807	28,519	30,534	27,789	24,605
Mitsubishi Pharma		[72,335]	47,239	47,913	50,482	50,528
Capital expenditure on an accrual basis						
Tanabe Seiyaku	<b>12,175</b>	5,968	4,368	4,156	3,834	8,722
Mitsubishi Pharma		[9,987]	5,412	8,645	13,099	11,975
Depreciation and amortization						
Tanabe Seiyaku	<b>15,658</b>	12,555	6,774	7,641	8,413	8,054
Mitsubishi Pharma		[15,085]	10,602	11,796	11,457	12,440
Total assets						
Tanabe Seiyaku	<b>810,756</b>	807,261	297,087	280,813	269,048	266,244
Mitsubishi Pharma			323,364	307,052	290,628	296,200
Total net assets <sup>2</sup>						
Tanabe Seiyaku	<b>666,220</b>	667,808	233,595	218,128	203,822	193,216
Mitsubishi Pharma			253,242	231,541	205,981	197,541
Interest-bearing debt						
Tanabe Seiyaku	<b>7,469</b>	8,151	132	693	1,695	1,881
Mitsubishi Pharma			8,485	8,819	11,192	16,798
Net cash provided by operating activities						
Tanabe Seiyaku	<b>50,540</b>	38,096	21,419	22,688	19,805	28,974
Mitsubishi Pharma		[46,447]	28,072	37,029	27,433	33,487
Net cash provided by (used in)						
investing activities						
Tanabe Seiyaku	<b>(74,508)</b>	(4,829)	(8,525)	(16,826)	(24,809)	1,271
Mitsubishi Pharma		[(8,981)]	4,357	(9,872)	(6,950)	20,475
Net cash used in financing activities						
Tanabe Seiyaku	<b>(15,986)</b>	(6,070)	(6,059)	(8,486)	(5,102)	(13,332)
Mitsubishi Pharma		[(9,097)]	(11,239)	(7,812)	(10,586)	(42,338)
Cash and cash equivalents at end of year						
Tanabe Seiyaku	<b>116,903</b>	160,096	46,121	39,249	41,941	51,963
Mitsubishi Pharma			85,182	63,812	44,192	34,196

	2009	2008 <sup>1</sup>	2007	2006	2005	2004
<b>Per share amounts (yen):</b>						
Net income—basic						
Tanabe Seiyaku	<b>¥47.28</b>	¥50.12	¥82.36	¥62.43	¥63.70	¥69.06
Mitsubishi Pharma			53.02	45.39	29.02	23.81
Net income—diluted						
Tanabe Seiyaku	—	—	—	62.43	63.68	69.06
Mitsubishi Pharma			—	—	—	—
Net assets <sup>2</sup>						
Tanabe Seiyaku	<b>1,162.69</b>	1,163.96	948.30	890.21	822.43	775.48
Mitsubishi Pharma			531.95	505.01	454.94	435.9
Cash dividends						
Tanabe Seiyaku	<b>28.00</b>	26.00 <sup>3</sup>	24.00	20.00	17.00	14.00
Mitsubishi Pharma			14.15	20.44	10.00	10.00
<b>Financial indicators (%):</b>						
Ratio of cost of sales						
Tanabe Seiyaku	<b>38.1%</b>	35.9%	38.9%	36.1%	37.0%	36.7%
Mitsubishi Pharma		[36.8]	35.2	34.5	34.9	35.6
Ratio of SG&A expenses						
Tanabe Seiyaku	<b>44.6</b>	47.0	44.0	47.8	47.0	46.3
Mitsubishi Pharma		[45.5]	47.2	50.2	51.8	52.2
Operating margin						
Tanabe Seiyaku	<b>17.3</b>	17.1	17.2	16.1	16.0	17.0
Mitsubishi Pharma		[17.7]	17.6	15.3	13.3	12.2
Ratio of R&D expenses to net sales						
Tanabe Seiyaku	<b>17.6</b>	18.9	16.1	17.8	16.2	14.2
Mitsubishi Pharma		[17.7]	20.8	20.3	21.6	21.5
Equity ratio						
Tanabe Seiyaku	<b>80.5</b>	80.9	78.2	77.7	75.8	72.6
Mitsubishi Pharma			75.4	75.4	70.9	66.7
DE ratio						
Tanabe Seiyaku	<b>1.1</b>	1.2	0.1	0.3	0.8	1.0
Mitsubishi Pharma			3.4	3.8	5.4	8.5
ROA						
Tanabe Seiyaku	<b>3.3</b>	4.0	7.0	5.6	5.9	7.0
Mitsubishi Pharma		[4.5]	7.7	6.9	4.5	3.4
ROE						
Tanabe Seiyaku	<b>4.1</b>	4.9	9.0	7.3	8.0	9.5
Mitsubishi Pharma		[5.7]	10.2	9.5	6.5	5.6
Dividend payout ratio						
Tanabe Seiyaku	<b>37.6<sup>5</sup></b>	33.2 <sup>4</sup>	29.1	32.0	26.7	20.3
Mitsubishi Pharma			30.0	46.8	31.7	43.2
<b>Others:</b>						
Number of employees						
Tanabe Seiyaku	<b>10,030</b>	10,361	4,554	4,512	4,517	4,540
Mitsubishi Pharma			5,907	5,902	5,917	6,122
Number of common stock issued (thousands)						
Tanabe Seiyaku	<b>561,417</b>	561,417	267,598	267,598	267,598	267,598
Mitsubishi Pharma			458,435	458,435	458,435	458,435

1 Figures in brackets are based on the simple sum of the results of the former Tanabe Seiyaku and the former Mitsubishi Pharma.

2 Due to a change in accounting standards, figures for the year ended March 31, 2006 and prior years are total shareholders' equity.

3 Dividends per share is based on the sum of the interim dividends (¥13) of the former Mitsubishi Pharma and the year-end dividends (¥13) of Mitsubishi Tanabe Pharma.

4 Dividend payout ratio is calculated using Mitsubishi Tanabe Pharma's net income for the second half of the fiscal year (less amortization of goodwill and provision of reserve for HCV litigation) and Mitsubishi Tanabe Pharma's year-end dividends.

5 Dividend payout ratio is calculated using net income less amortization of goodwill and provision of reserve for HCV litigation.